$AIDX

20/20 Biolabs, Inc.

CIK:0001139685|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues	$ 730,571	$ 535,060	$ 1,083,946	$ 1,088,880
Cost of revenues	425,844	371,796	716,335	759,822
Gross profit	304,727	163,264	367,611	329,058
Operating expenses:
Sales, general and administrative	1,291,318	814,811	2,644,076	1,615,955
Research and development	257,632	194,124	411,114	330,955
Total operating expenses	1,548,950	1,008,935	3,055,190	1,946,910
Operating loss	(1,244,223)	(845,671)	(2,687,579)	(1,617,852)
Other (expense) income:
Interest expense	(272,245)	(935)	(539,254)	(1,675)
Interest income	14,476	5,673	21,129	14,131
Loss on change in fair value of warrant liability			(148,766)
Loss on issuance of convertible note	(4,236)		(326,595)
Other expense, net	(115)		(115)	(115)
Total other (expense) income	(262,120)	4,738	(993,601)	12,341
Provision for income taxes
Net loss	(1,506,343)	(840,933)	(3,681,180)	(1,605,511)
Deemed dividend on warrant modifications	(1,124,676)		(1,124,676)
Preferred stock dividends	(121,662)		(175,854)
Net loss attributable to common stockholders	$ (2,752,681)	$ (840,933)	$ (4,981,710)	$ (1,605,511)
Basic net loss per common share (in Dollars per share)	$ (0.26)	$ (0.17)	$ (0.54)	$ (0.33)
Diluted net loss per common share (in Dollars per share)	$ (0.26)	$ (0.17)	$ (0.54)	$ (0.33)
Weighted-average common shares outstanding, basic (in Shares)	10,790,722	4,823,125	9,230,710	4,823,125
Weighted-average common shares outstanding, diluted (in Shares)	10,790,722	4,823,125	9,230,710	4,823,125

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,681,180)	$ (1,605,511)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24,610	33,304
Stock based compensation	499,740	259,300
Amortization of license fees	13,125	11,250
Issuance of common stock for services	181,500
Loss on issuance of convertible note	322,359
Amortization of right-of-use assets, net of liabilities	(6,238)	(3,676)
Amortization of debt discount	515,583
Change in fair value of derivative liability	148,766
Changes in operating assets and liabilities:
Accounts receivable	(91,532)	(38,979)
Inventory	5,181	(14,496)
Prepaid expenses and other assets	2,014	53,770
Accounts payable	158,265	184,333
Accrued liabilities	(29,883)	192,468
Deferred revenue	43,270	(94,161)
Net cash used in operating activities	(1,894,420)	(1,022,398)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of intangible assets, including patents	(5,354)
License agreement	(7,500)
Net cash used in investing activities	(12,854)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable	250,000	70,000
Proceeds from issuance of Series D preferred stock		192,338
Proceeds from issuance of series E convertible preferred stock	6,000,000
Offering costs	(822,573)
Net cash provided by financing activities	5,427,427	262,338
Increase (decrease) in cash and cash equivalents	3,520,153	(760,060)
Cash and cash equivalents, beginning of period	1,025,987	1,784,009
Cash and cash equivalents, end of period	4,546,140	1,023,949
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-cash disclosures of cash flow information:
Conversion of preferred stock to common stock	289,193
Deferred offering costs – issuance of common stock and warrants as offering costs	3,654,057
Accrued dividends on series E convertible preferred stock	121,662
Deemed dividend on warrant modifications	1,124,676
Issuance of preferred stock for dividends on series E convertible preferred stock	54,192
Derivative liabilities recognized as debt discounts	541,199
Derivative liabilities reclassified to equity	1,361,306
Conversion of convertible notes payable and accrued interest to common stock	834,812
Conversion of convertible notes payable and accrued interest to Series E Preferred	$ 583,197

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 4,546,140	$ 1,025,987
Accounts receivable, net	291,486	199,954
Inventory	111,036	116,217
Prepaid expenses and other current assets	126,961	128,975
Total current assets	5,075,623	1,471,133
License agreement, net	265,518	271,143
Property and equipment, net	33,700	56,677
Intangible asset, net	205,985	202,264
Right-of-use assets, net	519,302	605,289
Deferred financing costs		1,507,794
Other assets	23,057	23,057
Total assets	6,123,185	4,137,357
Current liabilities:
Accounts payable	1,026,809	868,545
Accrued liabilities	743,001	785,784
Accrued dividends – Series E convertible preferred stock	121,662
Deferred revenue – current	467,033	414,871
Derivative liability – current		143,382
Convertible notes payable – current		74,611
Operating lease liability – current	192,731	175,948
Total current liabilities	2,551,236	2,463,141
Long-term liabilities:
Convertible notes payable, net		619,355
Deferred revenue – long-term	32,924	41,816
Derivative liabilities – long-term		543,545
Operating lease liability – long term	379,717	488,725
Total long-term liabilities	412,641	1,693,441
Total liabilities	2,963,877	4,156,582
Commitments and contingencies (Note 9)
Stockholders’ equity (deficit):
Common stock, $0.01 par value; 50,000,000 authorized; 12,251,198 and 5,442,249 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	122,512	54,422
Additional paid-in capital	38,426,586	33,126,398
Accumulated deficit	(36,928,398)	(33,247,219)
Total stockholders’ equity (deficit)	1,620,700	(19,225)
Total liabilities, contingently redeemable preferred stock and stockholders’ equity	6,123,185	4,137,357
Series E Convertible Preferred Stock
Contingently redeemable convertible preferred stock:
Series E convertible preferred stock, $0.01 par value; 45,000 authorized; 5,228 and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; liquidation preference of $6,273,600	1,538,608
Series D Preferred Stock
Stockholders’ equity (deficit):
Preferred stock value		1,016
Series C Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred stock value		12,040
Series B Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred stock value		14,715
Series A-2 Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred stock value		6,515
Series A-1 Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred stock value		8,464
Series A Preferred Stock
Stockholders’ equity (deficit):
Preferred stock value		$ 4,424